Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in AustraliaOptimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in AustraliaUpdated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA
